ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

This study has been completed.

Sponsored by: Cerexa, Inc.
Information provided by: Cerexa, Inc.
ClinicalTrials.gov Identifier: NCT00424190
  Purpose

The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of complicated skin infections in adults.


Condition Intervention Phase
Bacterial Infections
Drug: vancomycin plus aztreonam
Drug: Ceftaroline
Phase III

MedlinePlus related topics:   Antibiotics    Bacterial Infections   

ChemIDplus related topics:   Vancomycin    Vancomycin hydrochloride    Aztreonam    Cefixime    Ceftaroline fosamil   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study
Official Title:   A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin and Skin Structure Infection

Further study details as provided by Cerexa, Inc.:

Primary Outcome Measures:
  • non-inferiority in clinical cure rate [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • microbiological success rate [ Designated as safety issue: No ]

Enrollment:   703
Study Start Date:   January 2007
Study Completion Date:   November 2007
Primary Completion Date:   November 2007 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
A: Experimental Drug: Ceftaroline
B: Active Comparator Drug: vancomycin plus aztreonam

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Skin and skin structure infection (SSSI) that involves deeper soft tissue or requires significant surgical intervention, or cellulitis or abscess on lower extremity which occurs in subjects with diabetes mellitus or well-documented peripheral vascular disease.

Exclusion Criteria:

  • Prior treatment of current cSSSI with an antimicrobial.
  • Failure of vancomycin or aztreonam as therapy for the current cSSSI, or prior isolation of an organism with in vitro resistance to vancomycin or aztreonam.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00424190

Show 52 study locations  Show 52 Study Locations

Sponsors and Collaborators
Cerexa, Inc.

Investigators
Principal Investigator:     Ralph Corey, MD     Duke University    
  More Information

Responsible Party:   Cerexa, Inc ( Sr. VP Clinical Development )
Study ID Numbers:   P903-06
First Received:   January 16, 2007
Last Updated:   January 8, 2008
ClinicalTrials.gov Identifier:   NCT00424190
Health Authority:   United States: Food and Drug Administration;   United States: Institutional Review Board;   Italy: National Bioethics Committee;   Italy: Ministry of Health;   Germany: Ethics Commission;   Germany: Federal Institute for Drugs and Medical Devices;   Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products;   Poland: Ministry of Health;   Switzerland: Ethikkommision;   Switzerland: Swissmedic;   Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica;   Argentina: Human Research Bioethics Committee;   Brazil: National Committee of Ethics in Research;   Brazil: Ministry of Health;   Brazil: National Health Surveillance Agency;   Chile: Comisión Nacional de Investigación Científica y Tecnológica;   Chile: Instituto de Salud Publica de Chile;   Mexico: Ethics Committee;   Mexico: Ministry of Health;   Mexico: Federal Commission for Protection Against Health Risks;   Peru: Ethics Committee;   Peru: General Directorate of Pharmaceuticals, Devices, and Drugs;   Peru: Ministry of Health;   Romania: National Medicines Agency;   Romania: State Institute for Drug Control;   Russia: Ethics Committee;   Russia: Ministry of Health and Social Development of the Russian Federation;   Ukraine: Ministry of Health;   Ukraine: State Pharmacological Center - Ministry of Health

Keywords provided by Cerexa, Inc.:
Abscess  
Antibacterial  
Antibiotic  
Antimicrobial  
Bacterial infection, skin  
Ceftaroline  
Ceftaroline acetate  
Cellulitis  
Cephalosporin  
Complicated skin and skin structure infection  
cSSSI  
Intravenous
MRSA
PPI-0903
Prodrug
Skin disease, bacterial
Skin infection
Staphylococcal skin infection
Staphylococcus aureus
Streptococcal skin infection
Surgical site infection
TAK-599

Study placed in the following topic categories:
Bacterial Infections
Aztreonam
Cephalosporins
Skin Diseases, Infectious
Cellulitis
Skin Diseases
Skin Diseases, Bacterial
Abscess
Cefixime
Vancomycin
Staphylococcal Skin Infections

Additional relevant MeSH terms:
Anti-Infective Agents
Anti-Bacterial Agents
Communicable Diseases
Therapeutic Uses
Infection
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 05, 2008




Links to all studies - primarily for crawlers